Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.
Clinical trial NCT07654530 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07654530
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-24
- Primary completion
- 2028-06-30
- Enrollment
- 107
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.